Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CuVIC-2 Trial of evolocumab after coronary stenting
jRCTs071200032Completed
- Sponsor
- Amgen
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of evolocumab in hypercholesterolemia and coronary arteriosclerosis (2 arms), sponsored by Amgen. Primary endpoint: Severity of coronary vasoconstriction. Started Nov 2020; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiacoronary arteriosclerosis
Beyond the preview
Go deeper on jRCTs071200032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200032.